Teratogenic Risk Impact Mitigation (TRIM): Development of Explicit Criteria to Facilitate Decisions Regarding Teratogenic Risk Mitigation Strategies

• Celeste L. Y. EwigUniversity of Florida
• Yanning WangUniversity of Florida
• Nicole E. SmolinskiUniversity of Florida
• Gita A. ToyserkaniUnited States Food and Drug Administration
• Cynthia LaCivita
• Leila G. LackeyUnited States Food and Drug Administration
• Sara L. EggersUnited States Food and Drug Administration
• Leyla ŞahinUnited States Food and Drug Administration
• Reem Abu-RustumUniversity of Florida Health
• Brian T. BatemanStanford Medicine
• Anick BérardCentre Hospitalier Universitaire Sainte-Justine
• Christina ChambersUniversity of California San Diego
• Beth A. Choby
• Elizabeth Ann ConoverUniversity of Nebraska Medical Center
• Michael F. GreeneHarvard University
• Sonia Hernández–Dı́azHarvard University
• Denise J. JamiesonUniversity of Iowa Health Care
• Sarah Gloria ObičanUniversity of South Florida
• Janine E. PolifkaUniversity of Washington
• Kay Roussos-RossUniversity of Florida Health
• Jeanne S. SheffieldJohns Hopkins Medicine
• Sharon Voyer LavigneUConn Health
• Ellen M. ZimmermannUniversity of Florida Health
• Susan B. LaffanAmgen (United States)
• Anthony M. DeLiseNovartis (United States)
• Alicia GilsenanRTI Health Solutions
• Tarek A. Hammad
• Christian HamppRegeneron (United States)
• Janet R. Hardy
• Caitlin A. KnoxRegeneron (United States)
• Kristine E. Shields
• Meredith Y. SmithUniversity of Southern California
• Rachel E. SobelRegeneron (United States)
• Melissa Sherman Tassinari
• Judith C. MaroHarvard University
• Sonja A. RasmussenJohns Hopkins University
• Almut Gertrud WintersteinUniversity of Florida Health